Q-omics provides the consensus-scored FAM3C profile across patient tissues and cancer cell-line models. FAM3C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM3C is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM3C RNA expression shows 19,581 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where FAM3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM3C survival associations across molecular data types. FAM3C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM3C RNA expression–survival associations across cancer types. High FAM3C expression shows unfavorable associations in KIRP, PAAD, HNSC, KICH and LGG, but favorable associations in ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM3C RNA expression.
This table summarizes FAM3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM3C shows higher tumor expression in HNSC, LUAD, LUSC, BLCA, THCA and CHOL. The HNSC box plot shows higher FAM3C RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with FAM3C in patient tissues and cancer cell lines. In patient samples, FAM3C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
